# US 12,600,770 B2 · Antibodies to connective tissue growth factor (CTGF) and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,600,770 B2
- Document ID: US12600770B2
- Status: Granted
- Kind: B2
- Application number: 19/065,094
- Filed: 2025-02-27
- Published: 2025-09-04
- Granted: 2026-04-14
- Earliest claimed: 2024-03-01
- Assignees: Boehringer Ingelheim International GmbH
- Applicants: Boehringer Ingelheim International GmbH
- Inventors: Andreas-David Brunner; Lars Dittus; Priyanka Gupta; Muriel Lize; Maria Bonatsakis Myzithras; Irina Rybina; Julia Sauer; Wioletta Anna Skronska-Wasek; Heiko Friedrich Stahl
- Web page: https://patentgrep.com/patent/US12600770B2

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61P 11/00: Drugs for disorders of the respiratory system
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure generally relates to anti-CTGF (connective tissue growth factor) antibodies or antigen-binding fragments thereof. Exemplary anti-CTGF antibodies disclosed herein address the need for treatments of conditions modulated by CTGF signaling. In some aspects, the anti-CTGF antibodies or antigen-binding fragments thereof are for diagnostic and/or therapeutic use, for example in a subject in need thereof, such as a human.

## Claims

### Claim 1

An anti-CTGF antibody or an antigen-binding fragment thereof, comprising:
i. a light chain variable region comprising an L-CDR1 having the amino acid sequence of SEQ ID NO: 220, an L-CDR2 having the amino acid sequence of SEQ ID NO: 221, and an L-CDR3 having the amino acid sequence of SEQ ID NO: 222; and a heavy chain variable region comprising an H-CDR1 having the amino acid sequence of SEQ ID NO: 105, an H-CDR2 having the amino acid sequence of SEQ ID NO: 106, and an H-CDR3 having the amino acid sequence of SEQ ID NO: 107; or
ii. a light chain variable region comprising an L-CDR1 having the amino acid sequence of SEQ ID NO: 100, an L-CDR2 having the amino acid sequence of SEQ ID NO: 101, and an L-CDR3 having the amino acid sequence of SEQ ID NO: 102; and a heavy chain variable region comprising an H-CDR1 having the amino acid sequence of SEQ ID NO: 105, an H-CDR2 having the amino acid sequence of SEQ ID NO: 106, and an H-CDR3 having the amino acid sequence of SEQ ID NO: 107; or
iii. a light chain variable region comprising an L-CDR1 having the amino acid sequence of SEQ ID NO: 110, an L-CDR2 having the amino acid sequence of SEQ ID NO: 111, and an L-CDR3 having the amino acid sequence of SEQ ID NO: 112; and a heavy chain variable region comprising an H-CDR1 having the amino acid sequence of SEQ ID NO: 105, an H-CDR2 having the amino acid sequence of SEQ ID NO: 106, and an H-CDR3 having the amino acid sequence of SEQ ID NO: 107; or
iv. a light chain variable region comprising an L-CDR1 having the amino acid sequence of SEQ ID NO: 100, an L-CDR2 having the amino acid sequence of SEQ ID NO: 101, and an L-CDR3 having the amino acid sequence of SEQ ID NO: 102; and a heavy chain variable region comprising an H-CDR1 having the amino acid sequence of SEQ ID NO: 115, an H-CDR2 having the amino acid sequence of SEQ ID NO: 116, and an H-CDR3 having the amino acid sequence of SEQ ID NO: 117; or
v. a light chain variable region comprising an L-CDR1 having the amino acid sequence of SEQ ID NO: 110, an L-CDR2 having the amino acid sequence of SEQ ID NO: 111, and an L-CDR3 having the amino acid sequence of SEQ ID NO: 112; and a heavy chain variable region comprising an H-CDR1 having the amino acid sequence of SEQ ID NO: 115, an H-CDR2 having the amino acid sequence of SEQ ID NO: 116, and an H-CDR3 having the amino acid sequence of SEQ ID NO: 117; or
vi. a light chain variable region comprising an L-CDR1 having the amino acid sequence of SEQ ID NO: 220, an L-CDR2 having the amino acid sequence of SEQ ID NO: 221, and an L-CDR3 having the amino acid sequence of SEQ ID NO: 222; and a heavy chain variable region comprising an H-CDR1 having the amino acid sequence of SEQ ID NO: 115, an H-CDR2 having the amino acid sequence of SEQ ID NO: 116, and an H-CDR3 having the amino acid sequence of SEQ ID NO: 117; or
vii. a light chain variable region comprising an L-CDR1 having the amino acid sequence of SEQ ID NO: 100, an L-CDR2 having the amino acid sequence of SEQ ID NO: 101, and an L-CDR3 having the amino acid sequence of SEQ ID NO: 102; and a heavy chain variable region comprising an H-CDR1 having the amino acid sequence of SEQ ID NO: 145, an H-CDR2 having the amino acid sequence of SEQ ID NO: 146, and an H-CDR3 having the amino acid sequence of SEQ ID NO: 147; or
viii. a light chain variable region comprising an L-CDR1 having the amino acid sequence of SEQ ID NO: 110, an L-CDR2 having the amino acid sequence of SEQ ID NO: 111, and an L-CDR3 having the amino acid sequence of SEQ ID NO: 112; and a heavy chain variable region comprising an H-CDR1 having the amino acid sequence of SEQ ID NO: 145, an H-CDR2 having the amino acid sequence of SEQ ID NO: 146, and an H-CDR3 having the amino acid sequence of SEQ ID NO: 147; or
ix. a light chain variable region comprising an L-CDR1 having the amino acid sequence of SEQ ID NO: 220, an L-CDR2 having the amino acid sequence of SEQ ID NO: 221, and an L-CDR3 having the amino acid sequence of SEQ ID NO: 222; and a heavy chain variable region comprising an H-CDR1 having the amino acid sequence of SEQ ID NO: 145, an H-CDR2 having the amino acid sequence of SEQ ID NO: 146, and an H-CDR3 having the amino acid sequence of SEQ ID NO: 147.

### Claim 2 (depends on 1)

The anti-CTGF antibody or an antigen-binding fragment thereof according to claim 1, wherein the anti-CTGF antibody or an antigen-binding fragment thereof comprises:
i. a light chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 223, and a heavy chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 108; or
ii. a light chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 103, and a heavy chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 108; or
iii. a light chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 113, and a heavy chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 108; or
iv. a light chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 103, and a heavy chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 118; or
v. a light chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 113, and a heavy chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 118; or
vi. a light chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 223, and a heavy chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 118; or
vii. a light chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 103, and a heavy chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 148; or
viii. a light chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 113, and a heavy chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 148; or
ix. a light chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 223, and a heavy chain variable region comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 148.

### Claim 3 (depends on 1)

The anti-CTGF antibody or an antigen-binding fragment thereof according to claim 1, wherein the anti-CTGF antibody or an antigen-binding fragment thereof comprises:
i. a light chain variable region comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 223, and a heavy chain variable region comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 108; or
ii. a light chain variable region comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 103, and a heavy chain variable region comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 108; or
iii. a light chain variable region comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 113, and a heavy chain variable region comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 108; or
iv. a light chain variable region comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 103, and a heavy chain variable region comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 118; or
v. a light chain variable region comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 113, and a heavy chain variable region comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 118; or
vi. a light chain variable region comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 223, and a heavy chain variable region comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 118; or
vii. a light chain variable region comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 103, and a heavy chain variable region comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 148; or
viii. a light chain variable region comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 113, and a heavy chain variable region comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 148; or
ix. a light chain variable region comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 223, and a heavy chain variable region comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 148.

### Claim 4 (depends on 1)

The anti-CTGF antibody or an antigen-binding fragment thereof according to claim 1, wherein the anti-CTGF antibody or an antigen-binding fragment thereof comprises:
i. a light chain variable region comprising the amino acid sequence of SEQ ID NO: 223, and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 108; or
ii. a light chain variable region comprising the amino acid sequence of SEQ ID NO: 103, and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 108; or
iii. a light chain variable region comprising the amino acid sequence of SEQ ID NO: 113, and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 108; or
iv. a light chain variable region comprising the amino acid sequence of SEQ ID NO: 123, and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 108; or
v. a light chain variable region comprising the amino acid sequence of SEQ ID NO: 133, and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 108; or
vi. a light chain variable region comprising the amino acid sequence of SEQ ID NO: 103, and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 118; or
vii. a light chain variable region comprising the amino acid sequence of SEQ ID NO: 113, and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 118; or
viii. a light chain variable region comprising the amino acid sequence of SEQ ID NO: 223, and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 118; or
ix. a light chain variable region comprising the amino acid sequence of SEQ ID NO: 103, and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 148; or
x. a light chain variable region comprising the amino acid sequence of SEQ ID NO: 113, and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 148; or
xi. a light chain variable region comprising the amino acid sequence of SEQ ID NO: 223, and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 148.

### Claim 5 (depends on 1)

The anti-CTGF antibody or antigen-binding fragment thereof according to claim 1, comprising:
i. a light chain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 224, and a heavy chain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 109; or
ii. a light chain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 104, and a heavy chain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 109; or
iii. a light chain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 114, and a heavy chain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 109; or
iv. a light chain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 104, and a heavy chain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 119; or
v. a light chain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 114, and a heavy chain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 119; or
vi. a light chain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 224, and a heavy chain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 119; or
vii. a light chain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 104, and a heavy chain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 149; or
viii. a light chain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 114, and a heavy chain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 149; or
ix. a light chain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 224, and a heavy chain comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO: 149.

### Claim 6 (depends on 1)

The anti-CTGF antibody or antigen-binding fragment thereof according to claim 1, comprising:
i. a light chain comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 224, and a heavy chain comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 109; or
ii. a light chain comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 104, and a heavy chain comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 109; or
iii. a light chain comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 114, and a heavy chain comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 109; or
iv. a light chain comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 104, and a heavy chain comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 119; or
v. a light chain comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 114, and a heavy chain comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 119; or
vi. a light chain comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 224, and a heavy chain comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 119; or
vii. a light chain comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 104, and a heavy chain comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 149; or
viii. a light chain comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 114, and a heavy chain comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 149; or
ix. a light chain comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 224, and a heavy chain comprising an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO: 149.

### Claim 7 (depends on 1)

The anti-CTGF antibody or antigen-binding fragment thereof according to claim 1, comprising:
i. a light chain comprising the amino acid sequence of SEQ ID NO: 224, and a heavy chain comprising the amino acid sequence of SEQ ID NO: 109; or
ii. a light chain comprising the amino acid sequence of SEQ ID NO: 104, and a heavy chain comprising the amino acid sequence of SEQ ID NO: 109; or
iii. a light chain comprising the amino acid sequence of SEQ ID NO: 114, and a heavy chain comprising the amino acid sequence of SEQ ID NO: 109; or
iv. a light chain comprising the amino acid sequence of SEQ ID NO: 104, and a heavy chain comprising the amino acid sequence of SEQ ID NO: 119; or
v. a light chain comprising the amino acid sequence of SEQ ID NO: 114, and a heavy chain comprising the amino acid sequence of SEQ ID NO: 119; or
vi. a light chain comprising the amino acid sequence of SEQ ID NO: 224, and a heavy chain comprising the amino acid sequence of SEQ ID NO: 119; or
vii. a light chain comprising the amino acid sequence of SEQ ID NO: 104, and a heavy chain comprising the amino acid sequence of SEQ ID NO: 149; or
viii. a light chain comprising the amino acid sequence of SEQ ID NO: 114, and a heavy chain comprising the amino acid sequence of SEQ ID NO: 149; or
ix. a light chain comprising the amino acid sequence of SEQ ID NO: 224, and a heavy chain comprising the amino acid sequence of SEQ ID NO: 149.

### Claim 8

An anti-CTGF antibody or antigen-binding fragment thereof, comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO: 113, and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 118.

### Claim 9

An anti-CTGF antibody or antigen-binding fragment thereof, comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO: 223, and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 108.

### Claim 10

An anti-CTGF antibody, comprising a light chain comprising the amino acid sequence of SEQ ID NO: 114, and a heavy chain comprising the amino acid sequence of SEQ ID NO: 149.

### Claim 11

An anti-CTGF antibody, comprising a light chain comprising the amino acid sequence of SEQ ID NO: 224, and a heavy chain comprising the amino acid sequence of SEQ ID NO: 109.

### Claim 12 (depends on 10)

The anti-CTGF antibody of claim 10, wherein said antibody comprises a light chain having an amino acid sequence consisting of SEQ ID NO: 114, and a heavy chain having an amino acid sequence consisting of SEQ ID NO: 149.

### Claim 13 (depends on 11)

The anti-CTGF antibody of claim 11, wherein said antibody comprises a light chain having an amino acid sequence consisting of SEQ ID NO: 224, and a heavy chain having an amino acid sequence consisting of SEQ ID NO: 109.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising the antibody or an antigen-binding fragment thereof according to claim 1, and a pharmaceutically acceptable carrier.

### Claim 15 (depends on 10)

A pharmaceutical composition comprising the antibody or an antigen-binding fragment thereof according to claim 10, and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 11)

A pharmaceutical composition comprising the antibody or an antigen-binding fragment thereof according to claim 11, and a pharmaceutically acceptable carrier.

### Claim 17 (depends on 1)

An isolated polynucleotide or plurality of isolated polynucleotides that encodes a sequence comprising the heavy chain variable region and/or light chain variable region of the antibody or an antigen-binding fragment thereof according to claim 1.

### Claim 18 (depends on 10)

An isolated polynucleotide or plurality of isolated polynucleotides that encodes a sequence comprising the heavy chain variable region and/or light chain variable region of the antibody or an antigen-binding fragment thereof according to claim 10.

### Claim 19 (depends on 11)

An isolated polynucleotide or plurality of isolated polynucleotides that encodes a sequence comprising the heavy chain variable region and/or light chain variable region of the antibody or an antigen-binding fragment thereof according to claim 11.

### Claim 20 (depends on 17)

A host cell comprising the polynucleotide or plurality of polynucleotides according to claim 17.

### Claim 21 (depends on 18)

A host cell comprising the polynucleotide or plurality of polynucleotides according to claim 18.

### Claim 22 (depends on 19)

A host cell comprising the polynucleotide or plurality of polynucleotides according to claim 19.

### Claim 23 (depends on 1)

A method for the production of an anti-CTGF antibody or antigen-binding fragment thereof according to claim 1, comprising the steps:
(a) cultivating a host cell comprising a polynucleotide or plurality of polynucleotides that encode said antibody or antigen-binding fragment thereof under conditions allowing the expression of the anti-CTGF antibody or antigen-binding fragment thereof; and
(b) recovering said anti-CTGF antibody or antigen-binding fragment thereof.

### Claim 24 (depends on 10)

A method for the production of an anti-CTGF antibody or antigen-binding fragment thereof according to claim 10, comprising the steps:
(a) cultivating a host cell comprising a polynucleotide or plurality of polynucleotides that encode said antibody or antigen-binding fragment thereof under conditions allowing the expression of the anti-CTGF antibody or antigen-binding fragment thereof; and
(b) recovering said anti-CTGF antibody or antigen-binding fragment thereof.

### Claim 25 (depends on 11)

A method for the production of an anti-CTGF antibody or antigen-binding fragment thereof according to claim 11, comprising the steps:
(a) cultivating a host cell comprising a polynucleotide or plurality of polynucleotides that encode said antibody or antigen-binding fragment thereof under conditions allowing the expression of the anti-CTGF antibody or antigen-binding fragment thereof; and
(b) recovering said anti-CTGF antibody or antigen-binding fragment thereof.

### Claim 26 (depends on 1)

An in-vitro method of inhibiting the interaction between human CTGF or human CTGF-NTF and a cell, comprising contacting said human CTGF with an effective amount of the anti-CTGF antibody or antigen-binding fragment thereof according to claim 1.

### Claim 27 (depends on 10)

An in-vitro method of inhibiting the interaction between human CTGF or human CTGF-NTF and a cell, comprising contacting said human CTGF with an effective amount of the anti-CTGF antibody or antigen-binding fragment thereof according to claim 10.

### Claim 28 (depends on 11)

An in-vitro method of inhibiting the interaction between human CTGF or human CTGF-NTF and a cell, comprising contacting said human CTGF with an effective amount of the anti-CTGF antibody or antigen-binding fragment thereof according to claim 11.

### Claim 29 (depends on 1)

The anti-CTGF antibody or antigen binding fragment thereof of claim 1, wherein said anti-CTGF antibody or antigen binding fragment thereof:
(a) is glycosylated; and/or
(b) comprises a heavy chain constant region selected from IgG1, IgG2, IgG3, IgG4, IgM, IgA and IgE; and/or
(c) comprises an IgG1 heavy chain constant region; and/or
(d) comprises a heavy chain lacking a C-terminal lysine residue; and/or
(e) comprises a light chain constant region selected from the group consisting of a kappa and a lambda light chain; and/or
(f) is a monoclonal antibody; and/or
(g) is a monospecific antibody; and/or
(h) is a human, humanized, or chimeric antibody; and/or
(i) binds human CTGF of SEQ ID NO: 2, with a KD of 5 pM or lower; and/or
(j) binds the N-terminal fragment of human CTGF of SEQ ID NO: 3 with a KD of 500 pM or lower.